Biosimilar Safety Considerations in Clinical Practice
Authors:
- 1 February 2014
- journal article
- Published by Elsevier in Seminars in Oncology
- Vol. 41, S3-S14
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA studyAnnals of the Rheumatic Diseases, 2013
- Biosimilars to treat inflammatory arthritis: the challenge of proving identityAnnals of the Rheumatic Diseases, 2013
- Update on the safety and bioequivalence of biosimilars – focus on enoxaparinDrug, Healthcare and Patient Safety, 2013
- Pharmacovigilance and biosimilars: considerations, needs and challengesExpert Opinion on Biological Therapy, 2013
- Biosimilar monoclonal antibodies: a science-based regulatory challengeExpert Opinion on Biological Therapy, 2013
- Biosimilars: what clinicians should knowBlood, 2012
- On the Regulatory Approval Pathway of Biosimilar ProductsPharmaceuticals, 2012
- NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety PerspectivesJournal of the National Comprehensive Cancer Network, 2011
- Biosimilars—why terminology mattersNature Biotechnology, 2011
- The challenge of biosimilarsAnnals of Oncology, 2007